Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Predictive Oncology's share price for the quarter that ended in Mar. 2024 was $2.55. Predictive Oncology's Shares Outstanding (EOP) for the quarter that ended in Mar. 2024 was 4.06 Mil. Therefore, Predictive Oncology's market cap for the quarter that ended in Mar. 2024 was $10.36 Mil.
Predictive Oncology's quarterly market cap
increased
from Sep. 2023 ($12.91 Mil) to Dec. 2023 ($13.37 Mil) but then
declined
from Dec. 2023 ($13.37 Mil) to Mar. 2024 ($10.36 Mil).
Predictive Oncology's annual market cap
declined
from Dec. 2021 ($62.46 Mil) to Dec. 2022 ($24.15 Mil) and
declined
from Dec. 2022 ($24.15 Mil) to Dec. 2023 ($13.37 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Predictive Oncology's Enterprise Value for Today is $2.39 Mil.
Predictive Oncology Market Cap Historical Data
The historical data trend for Predictive Oncology's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Predictive Oncology's Market Cap
For the Medical Instruments & Supplies subindustry, Predictive Oncology's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Predictive Oncology's Market Cap Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Predictive Oncology's Market Cap distribution charts can be found below:
* The bar in red indicates where Predictive Oncology's Market Cap falls into.
Predictive Oncology Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Predictive Oncology's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Predictive Oncology (NAS:POAI) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Predictive Oncology Market Cap Related Terms
Thank you for viewing the detailed overview of Predictive Oncology's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Predictive Oncology (Predictive Oncology) Business Description
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Helomics, zPREDICTA, Soluble and Skyline. It derives prime revenue from the Skyline segment which consists of the STREAMWAY System product sales, and TumorGenesis subsidiary (Research and Development) is included within corporate. The STREAMWAY System virtually eliminates staff exposure to blood, irrigation fluid, and other potentially infectious fluids found in the healthcare environment. Its Helomics division is focused on improving the effectiveness of cancer therapy using proprietary, multi-omic tumor profiling platform, a one-of-a-kind database of historical tumor data, and the power of AI to build predictive models of tumor drug response.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
POAI has been successfully added to your 